Advertisement

Drugs

, Volume 32, Supplement 4, pp 8–26 | Cite as

Aspirin and Related Derivatives of Salicylic Acid

  • Stephen P. Clissold
Article

Summary

After almost 90 years of clinical use, aspirin remains one of the world’s most extensively used ‘over-the-counter’ drugs, and it is still recognised as the standard analgesic/antipyretic/anti-inflammatory agent by which newer drugs are assessed. However, its pre-eminent position as the analgesic of choice for mild to moderate pain has been seriously challenged with the introduction of many ‘new’ non-steroidal non-narcotic analgesic drugs. Indeed, there is convincing scientific evidence that many of the ‘newer’ non-steroidal drugs such as diflunisal, ibuprofen, flurbiprofen etc. are significantly superior analgesics and, in many cases, have a longer duration of action.

In recent years the salicylates, aspirin in particular, have been the focus of much attention regarding their side effect profiles. At usual dosages for relief of pain and during occasional use, aspirin is well tolerated by the vast majority of patients. Adverse reactions, of which there is a wide spectrum, most frequently accompany anti-inflammatory doses of aspirin, or may be the result of accidental overdosing (particularly in children and the elderly) — probably a reflection of the lay population’s acceptability of aspirin’s presumed safety. As with other non-steroidal analgesic drugs, gastrointestinal complaints are the most commonly reported side effects.

The existence of many shared clinical, adverse and toxic effects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is thought to be accounted for by a common mechanism — inhibition of the ubiquitous cyclo-oxygenase enzyme. Thus, suppression of prostaglandin biosynthesis is widely considered to explain the common properties of NSAIDS, although further research is still necessary to clarify some inconsistencies and to complete our understanding of the processes involved.

Aspirin and salicylates have been reported to have a wide range of drug interactions but only relatively few seem to be clinically important. Many of the interactions are pharmacokinetic in nature. Drugs considered to produce the most significant interactions with salicylates include anticoagulants and thrombolytic agents, uricosuric agents, corticosteroids, methotrexate and sulphonylurea hypoglycaemic agents.

Keywords

Aspirin Salicylic Acid Salicylate Related Derivative Analgesic Nephropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Hospital Formulary: Analgesics and antipyretics; in Drug Information 85, pp. 705–733 (American Society of Hospital Pharmacists, Bethesda 1985).Google Scholar
  2. Borgå, O.; Odar-Cederlöf, I.; Rinberger, V. and Norlin, A.: Protein binding of salicylate in uremic and normal plasma. Clinical Pharmacology and Therapeutics 20: 464–475 (1976).PubMedGoogle Scholar
  3. Bowman, W.C. and Rand, M.J. (Eds): Textbook of Pharmacology (2nd ed.) (Blackwell Scientific Publications, Oxford 1980).Google Scholar
  4. Brogden, R.N.; Heel, R.C.; Pakes, G.E.; Speight, T.M. and Avery, G.S.: Diflunisal. Drugs 19: 84–106 (1980).PubMedCrossRefGoogle Scholar
  5. Brune, K. and Lanz, R.: Nonopioid analgesics; in Kuhar and Pasternak (Eds) Analgesics: Neurochemical Behavioural and Clinical Perspectives (Raven Press, New York 1984).Google Scholar
  6. Brune, K. and Lanz, R.: Pharmacokinetics of non-steroidal anti-inflammatory drugs; in Bonta et al. (Eds) The Pharmacology of Inflammation, Vol. 5 (Elsevier Science Publishers, New York 1985).Google Scholar
  7. Conti, L.; Fidani, P.; Chistolini, A.; Francesconi, M.; Gandolfo, G.M. and Mazzucconi, M.G.: Detection of drug dependent IgG antibodies with antiplatelet activity by the antiglobulin consumption assay. Haemostasis 14: 480–486 (1984).PubMedGoogle Scholar
  8. Cooper, S.A.: Comparative analgesic efficacies of aspirin and acetaminophen. Archives of Internal Medicine 141: 282–285 (1981).PubMedCrossRefGoogle Scholar
  9. Cooper, S.A.: New peripherally-acting oral analgesic agent. Annual Review of Pharmacology and Toxicology 23: 617–647 (1983).PubMedCrossRefGoogle Scholar
  10. Cooper, S.A. and Beaver, W.T.: A model to evaluate mild analgesics in oral surgery. Clinical Pharmacology and Therapeutics 20: 241–250 (1976).PubMedGoogle Scholar
  11. Crombie, D.L.; Pinsent, R.J.F.H.; Salter, B.C.; Fleming, D. and Cross, K.W.: Teratogenic drugs-RCGP survey. British Medical Journal 4: 178–179 (1970).PubMedCrossRefGoogle Scholar
  12. Dromgoole, S.H.; Furst, D.E. and Paulus, H.E.: Rational approaches to the use of salicylates in the treatment of rheumatoid arthritis. Seminars in Arthritis and Rheumatism 11: 257–283 (1981).CrossRefGoogle Scholar
  13. Dubas, T.S. and Parker, J.M.: A central component in the analgesic action of sodium salicylate. Archives Internationales de Pharmacodynamie et de Thérapie 194: 117–122 (1971).PubMedGoogle Scholar
  14. Editorial: Aspirin and the stomach. British Medical Journal 282: 91–92 (1981).Google Scholar
  15. Farah, A.E. and Rosenberg, F.: Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors. British Journal of Clinical Pharmacology 10: 251S–278S (1980).CrossRefGoogle Scholar
  16. Ferreira, S.H.; Moncada, S. and Vane, J.R.: Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature 231: 237–239 (1971).CrossRefGoogle Scholar
  17. Flower, R.J.; Moncada, S. and Vane, J.R.: Analgesic-antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout; in Goodman and Gilman (Eds) The Pharmacological Basis of Therapeutics (6th ed.) pp. 682–728 (Macmillan Publishing Company, New York 1980).Google Scholar
  18. Forbes, J.A.; Beaver, W.T.; White, E.H.; White, R.W.; Neilson, G.B. and Shackleford, R.W.: A new oral analgesic with an unusually long duration of action. Journal of the American Medical Association 248: 2139–2142 (1982a).PubMedCrossRefGoogle Scholar
  19. Forbes, J.A.; Calderazzo, J.P.; Bowser, M.W.; Foor, V.M.; Shackleford, R.W. and Beaver, W.T.: A 12-hour evaluation of the analgesic efficacy of diflunisal, aspirin, and placebo in postoperative dental pain. Journal of Clinical Pharmacology 22: 89–96 (1982b).PubMedGoogle Scholar
  20. Forbes, J.A.; Barkaszi, B.A.; Ragland, R.N. and Hankie, J.J.: Analgesic effect of fendosal, ibuprofen and aspirin in postoperative oral surgery pain. Pharmacotherapy 4: 385–391 (1984).PubMedGoogle Scholar
  21. Graham, G.G.; Champion, G.D.; Day, R.O. and Pauli, P.D.: Patterns of plasma concentrations and urinary excretion of salicylates in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 22: 410–420 (1977).PubMedGoogle Scholar
  22. Hanks, G.W.: Mild analgesics: a review of their efficacy, adverse effects and safety. 1. Aspirin. Clinical Therapeutics (Suppl. A): 1–23 (1982).Google Scholar
  23. Hubert, D.; Habibi, B.; Krulik, M. and Debray, J.: Anémie hé-molytique immunoallergique, thrombopénie et insuffisance rénale aiguë induites par l’aspirine. La Presse Médicale 13: 2567–2569 (1984).PubMedGoogle Scholar
  24. Hull Hayes, A.: Therapeutic implications of drug interactions with acetaminophen and aspirin. Archives of Internal Medicine 141: 301–304 (1981).CrossRefGoogle Scholar
  25. Ivey, K.J.: Gastrointestinal effects of antipyretic analgesics. American Journal of Medicine 75: 53–64 (1983).PubMedCrossRefGoogle Scholar
  26. Jick, H.: Effects of aspirin and acetaminophen in gastrointestinal hemorrhage. Archives of Internal Medicine 141: 316–321 (1981).PubMedCrossRefGoogle Scholar
  27. Kay, A.B.: The immunological basis of asthma; in Clark (Ed.) Steroids in Asthma, pp. 46–60 (ADIS Press, Auckland 1983).Google Scholar
  28. Klinenberg, J. and Miller, F.: Effect of corticosteroids on blood salicylate concentration. Journal of the American Medical Association 194: 131–134 (1965).CrossRefGoogle Scholar
  29. Lasagna, L.: Analgesic drugs. American Journal of Medical Sciences 242: 620–627 (1961).Google Scholar
  30. Levy, G.: Pharmacokinetics of salicylate elimination in man. Journal of Pharmaceutical Sciences 54: 959–967 (1965).PubMedCrossRefGoogle Scholar
  31. Levy, G.: Drug biotransformation interactions in man. Annals of the New York Academy of Sciences 71: 32–42 (1971).CrossRefGoogle Scholar
  32. Levy, G.: Pharmacokinetics of salicylates in man. Drug Metabolism Reviews 9: 3–19 (1979).PubMedCrossRefGoogle Scholar
  33. Levy, G.: Clinical pharmacokinetics of salicylates. British Journal of Clinical Pharmacology 10: 285S–290S (1981).CrossRefGoogle Scholar
  34. Levy, M.: Aspirin use in patients with major upper gastrointestinal bleeding and peptic ulcer disease. New England Journal of Medicine 290: 1158–1162 (1974).PubMedCrossRefGoogle Scholar
  35. Levy, G. and Hollister, L.E.: Dissolution rate limited absorption in man. Journal of Pharmaceutical Sciences 54: 1121–1125 (1965).PubMedCrossRefGoogle Scholar
  36. Levy, G. and Tsuchiya, T.: Salicylate accumulation kinetics in man. New England Journal of Medicine 287: 430–432 (1972).PubMedCrossRefGoogle Scholar
  37. Lim, R.K.: Salicylate analgesia; in Smith and Smith (Eds) The Salicylates, pp. 155–202 (Interscience Publishers, New York 1966).Google Scholar
  38. Lim, R.K.; Guzman, F.; Rodgers, D.W.; Goto, K.; Braun, G.D. et al.: Site of action of narcotic and non-narcotic analgesics determined by blocking bradykinin evoked visceral pain. Archives Internationales de Pharmacodynamie et de Thérapie 152: 25–58 (1964).PubMedGoogle Scholar
  39. McDonald-Gibson, W.J.; McDonald-Gibson, R.G.; Power, G.M. and Collier, H.O.J.: The effect of acetylsalicylate on aggregation and arachidonate metabolism by human platelets suspended in plasma or buffer. Prostaglandins Leukotrienes and Medicine 15: 1–14 (1984).CrossRefGoogle Scholar
  40. Mehlisch, D.R.: Review of the comparative analgesic efficacy of salicylates, acetaminophen, and pyrazolones. American Journal of Medicine 75: 47–52 (1983).PubMedCrossRefGoogle Scholar
  41. Melzack, R.; Jeans, M.E.; Kinch, R.A. and Katz, J.: Diflunisal (1000mg single dose) versus acetaminophen (650mg) and placebo for the relief of post-episiotomy pain. Current Therapeutic Research 34: 929–939 (1983).Google Scholar
  42. Mielke, C.H.: Comparative effects of aspirin and acetaminophen on hemostasis. Archives of Internal Medicine 141: 305–310 (1981).PubMedCrossRefGoogle Scholar
  43. Miller, D.R.: Aspirin: a new look. U.S. Pharmacist 7: 43–53 (1982).Google Scholar
  44. Moertel, C.G.; Ahmann, D.L.; Taylor, W.F. and Schwartau, N.: A comparative evaluation of marketed analgesic drugs. New England Journal of Medicine 286: 813–815 (1972).PubMedCrossRefGoogle Scholar
  45. Moncada, S.; Flower, R.J. and Vane, J.R.: Prostaglandins, prostacyclin, and thromboxane A2, in Goodman and Gilman (Eds) The Pharmacological Basis of Therapeutics (6th ed.) pp. 668–681 (Macmillan Publishing Company, New York 1980).Google Scholar
  46. Needs, C.J. and Brooks, P.M.: Clinical pharmacokinetics of the salicylates. Clinical Pharmacokinetics 10: 164–177 (1985).PubMedCrossRefGoogle Scholar
  47. Nitelius, E.; Brantmark, B.; Fredholm, B.; Hedner, U.; Plym Forshell, G.; Wåhlin-Boll, E. and Melander, A.: Actions and interactions of acetylsalicylic acid, salicylic acid and diflunisal on platelet aggregation. European Journal of Clinical Pharmacology 27: 165–168 (1984).PubMedCrossRefGoogle Scholar
  48. Orlowski, J.P.: Aspirin and Reye’s syndrome. Postgraduate Medicine 75: 47–54 (1984).PubMedGoogle Scholar
  49. Piper, D.: Aspirin and the gastrointestinal tract. Australian Journal of Pharmacy 64: 680–682 (1983).Google Scholar
  50. Prescott, L.F.: Analgesic nephropathy. Drugs 23: 75–149 (1982).PubMedCrossRefGoogle Scholar
  51. Proudfoot, A.T.: Toxicity of salicylates. American Journal of Medicine 75: 99–103 (1983).PubMedCrossRefGoogle Scholar
  52. Quiding, H.; Nyström, E. and Gustatsson, I.: Analgesic efficacy and pain intensity at dose intake. Clinical Pharmacology and Therapeutics 37: 222 (1985).Google Scholar
  53. Rainsford, K.D.; Schweitzer, A. and Brune, K.: Distribution of acetyl compared to salicyl moiety of acetylsalicylic acid. Biochemical Pharmacology 32: 1307–1308 (1983).CrossRefGoogle Scholar
  54. Rao, S.K. and Sharma, S.K.: The efficacy and safety of Dolobid and Distalgesic in post-traumatic pain and immobility. British Journal of Clinical Practice 36: 266–285 (1982).PubMedGoogle Scholar
  55. Rees, W.D.W. and Turnberg, L.A.: Reappraisal of the effects of aspirin on the stomach. Lancet 2: 410–413 (1980).PubMedCrossRefGoogle Scholar
  56. Reye, R.D.K.; Morgan, G. and Baral, J.: Encephalopathy and fatty degeneration of the viscera: a disease entity in childhood. Lancet 2: 749–752 (1963).PubMedCrossRefGoogle Scholar
  57. Rowland, M. and Riegelman, S.: Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. Journal of Pharmaceutical Sciences 57: 1313–1319 (1968).CrossRefGoogle Scholar
  58. Rowland, M.; Riegelman, S.; Harris, P.A. and Sholkoff, S.D.: Absorption kinetics of aspirin in man following oral administration of an aqueous solution. Journal of Pharmaceutical Sciences 61: 379–385 (1972).PubMedCrossRefGoogle Scholar
  59. Sause, R.; Weisman, R.S. and Howland, A.: The use of aspirin. Physician Assistant and Health Practitioner 6: 43–50 (1982).Google Scholar
  60. Settipane, G.A.: Aspirin and allergic diseases. American Journal of Medicine 74: 102–109 (1983).PubMedCrossRefGoogle Scholar
  61. Seymour, R.A.: Aspirin in dentistry. Australian Journal of Pharmacy 64: 900–903 (1983).Google Scholar
  62. Seymour, R.A. and Rawlins, M.D.: The efficacy and pharmacokinetics of aspirin in postoperative dental pain. British Journal of Clinical Pharmacology 13: 807–810 (1982).PubMedCrossRefGoogle Scholar
  63. Seymour, R.A.; Rawlins, M.D. and Clothier, A.: The efficacy and pharmacokinetics of sodium salicylate in post-operative dental pain. British Journal of Clinical Pharmacology 17: 161–163 (1984).PubMedCrossRefGoogle Scholar
  64. Slone, D.; Heinonen, P.O.; Kaufman, D.W.; Siskind, V.; Monson, R.R. and Shapiro, S.: Aspirin and congenital malformations. Lancet 1: 1373–1375 (1976).PubMedCrossRefGoogle Scholar
  65. Smith, J.B. and Willis, A.L.: Aspirin selectivity inhibits prostaglandin production in human platelets. Nature 231: 235–237 (1971).Google Scholar
  66. Starmer, G.: The history of aspirin and its mode of action. Australian Journal of Pharmacy 64: 70–72 (1983).Google Scholar
  67. Szczeklik, A.: Antipyretic analgesics and the allergic patient. American Journal of Medicine 75: 82–84 (1983).PubMedCrossRefGoogle Scholar
  68. Taylor, F.: Aspirin: America’s favourite drug. FDA Consumer 14: 13–16 (1980–81).Google Scholar
  69. Thomas, J.: Aspirin — a remarkable drug. Australian Journal of Pharmacy 64: 713–720 (1983a).Google Scholar
  70. Thomas, J.: Profile on aspirin. Australian Journal of Pharmacy 64: 794–803 (1983b).Google Scholar
  71. Turner, G. and Collins, E.: Fetal effects of regular salicylate ingestion in pregnancy. Lancet 2: 338–339 (1975).PubMedCrossRefGoogle Scholar
  72. Vane, J.R.: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231: 232–235 (1971).Google Scholar
  73. Vane, J.R.: Prostaglandins and aspirin-like drugs; in Maxwell and Acheson (Eds) Cellular Mechanisms, Vol. 5 (Karger, Basel 1973).Google Scholar
  74. Vane, J.R.: Aspirin; in Breckenridge (Ed.) Advanced Medicine: Topics in Therapeutics, 1 (Pitman Medical Publishing Company, London 1975).Google Scholar
  75. Von Graffenried, B.; Nuesch, E.; Maeglin, B.; Hagler, W. and Kuhn, M.: Assessment of analgesics in dental surgery outpatients. European Journal of Clinical Pharmacology 18: 479–482 (1980).CrossRefGoogle Scholar
  76. Webster, J.: Interactions of NSAIDs with diuretics and β-blockers. Drugs 30: 32–41 (1985).PubMedCrossRefGoogle Scholar
  77. White, P. and Strunin, L.: Post-anaesthetic dental extraction analgesia: a comparison of paracetamol, codeine, caffeine (Solpadeine) and diflunisal (Dolobid). British Journal of Oral Surgery 20: 275–280 (1982).PubMedCrossRefGoogle Scholar
  78. Wilson, J.T.; Howell, R.L.; Holladay, M.W.; Brilis, G.M.; Chrastil, J.; Watson, J.T. and Taber, D.F.: Gentisuric acid: metabolic formation in animals and identification as a metabolite of aspirin in man. Clinical Pharmacology and Therapeutics 23: 635–643 (1978).PubMedGoogle Scholar
  79. Wilson, J.T.; Brown, R.D.; Bocchini, J.A. and Kearns, G.L.: Efficacy, disposition and pharmacodynamics of aspirin, acetaminophen and choline salicylate in young febrile children. Therapeutic Drug Monitoring 4: 147–180 (1982).PubMedCrossRefGoogle Scholar
  80. Woods, R.L.: Aspirin and cancer. Australian Journal of Pharmacy 64: 514–518 (1983).Google Scholar
  81. Zimmerman, H.J.: Effects of aspirin and acetaminophen on the liver. Archives of Internal Medicine 141: 333–342 (1981).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1986

Authors and Affiliations

  • Stephen P. Clissold
    • 1
  1. 1.ADIS Drug Information ServicesMairangi Bay, Auckland 10New Zealand

Personalised recommendations